This site is intended for healthcare professionals

Predstavenie titulu

Novinky z tohtoročného najvýznamnejšieho stretnutia onkológov 2017

Originálny názov:
Novinky z tohtoročného najvýznamnejšieho stretnutia onkológov

Dátum vydania: 09/2017


Formát: 210×270 mm

Počet strán: 120

Väzba: V1 ?Listy jsou spojeny sponkou ve hřbetu

Jazyk: Slovenčina

Náhľad PDF


Anotácia

Toto vydanie Event Reportu zhŕňa dianie na konferencii Americkej spoločnosti klinickej onkológie, ktorá sa konala v júni 2017 v americkom Chicagu. Pôvodné informácie sumarizujú to najdôležitejšie, čo zaznelo v gastrointestinálnej či gynekologickej sekcii, ďalej v sekcii rakoviny prsníka, genitourinárnych malignít, rakoviny pľúc a melanómu. Pôvodné informácie sú doplnené vybranými abstraktmi prednášok.



Obsah

Najvýznamnejšie klinické správy z konferencie ASCO 2017 v problematike nádorov gastrointestinálneho traktu
Radovan Barilla
 
Post-Surgery Capecitabine ‘Should Become Standard of Care’ in Biliary Tract Cancers
Michelle Dalton
 
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study
 
Risk-Based Approach to Chemotherapy Duration Recommended for Stage III Colon Cancer
Tim Donald
 
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
 
Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)
 
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
 
Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
 
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer
 
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study
 
Aktuální výsledky klinických studií
Katarína Petráková
 
Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer
Dave Levitan
 
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
 
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
 
Pertuzumab Reduced Risk of Invasive Disease–Free Survival Compared With Placebo in APHINITY
Michelle Dalton
 
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
 
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).
 
Phase II study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A
 
A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03)
 
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
 
Gynekologické malignity – stručný výber z prác prezentovaných na ASCO Annual Meeting 2017
Juraj Beniak
 
Strategic Combinations in Ovarian Cancer
 
LION: Lymphadenectomy in ovarian neoplasms – A prospective randomized AGO study group led gynecologic cancer intergroup trial
 
An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers
 
Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study
 
Treatment and outcomes of small cell neuroendocrine carcinoma of the cervix (SCCC)
 
Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer
 
A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma
 
Circulating tumor DNA analysis using targeted sequencing of 508 clinically actionable genes in patients with high grade serous ovarian cancer
 
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer
 
SPRÁVA Z VÝROČNEJ KONFERENCIE AMERICKEJ ONKOLOGICKEJ SPOLOČNOSTI 2017 Genitourinárne malignity
 
Genomics May Provide New Insight Into Bladder Cancer Treatments
Michelle Dalton
 
DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC)
 
Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B)
 
KEYNOTE-045: Pembrolizumab Maintains Overall Survival Benefit in Urothelial Cancer
Debra Gordon
 
Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC)
 
Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas
 
Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
 
A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC)
 
KARCINÓM PĽÚC NA ASCO 2017
Peter Beržinec
 
Education Session Reviews Current Management of Early-Stage NSCLC, Offers Glimpse of Future Advances
Kara Nyberg
 
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)
 
Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer
 
Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012
 
First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G
 
Alectinib Versus Crizotinib in Treatment-Naive Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC): Primary Results of the Global Phase III ALEX Study
 
Efficacy of the Addition of Cisplatin to Single-Agent First-Line Chemotherapy in Elderly Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Joint Analysis of the Multicenter, Randomized Phase III MILES-3 and MILES-4 studies
 
Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts)
 
KONGRES ASCO 2017 PRINIESOL ŠTYRI HLAVNÉ KLINICKY KRITICKÉ SPRÁVY V LIEČBE MALÍGNEHO MELANÓMU
 
Combined Checkpoint Inhibition Ushers in a New Era of CNS Therapy in Melanoma
 
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204
 
A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC)
 
Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment
 
COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM)
 
Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM)
 

Tiráž

Vydavateľ: We Make Media Slovakia s.r.o. | Konateľka: MUDr. Ivana Kaderková | Adresa: Bárdošova 2/A, 831 01 Bratislava, Slovenská republika | Tel.: +421 948 422 117 | E-mail: info@wemakemedia.sk | www.wemakemedia.sk
Zodpovedná redaktorka: Veronika Lazarová | Jazyková redaktorka: Mgr. Anetta Letková
Zlom a grafická úprava: We Make Media Slovakia s.r.o. | ISBN: 978 – 80 – 972221 – 4 – 7 | Vyšlo: september 2017

Akékoľvek kopírovanie a šírenie celého obsahu alebo časti tohto časopisu, či už v tlačenej, alebo elektronickej podobe, je bez výslovného súhlasu vydavateľa prísne zakázané.
Vychádza 1 x ročne | 2. ročník | V publikácii boli s povolením Americkej spoločnosti klinickej onkológie použité texty a fotografie zo zdroja:
http://am.asco.org. Texts and photos from the source http://am.asco.org are used with permission of the American Society of Clinical Oncology.
All rights reserved. © 2017 American Society of Clinical Oncology.



Komercia

Partneři projektu